In an environment where the medical establishment has been slow to accept new technology and therapies, the patient plays an important role in driving the adoption of new therapies. As patients continue to hear about and understand new therapies that yield better health outcomes, their active participation in contributing their clinical data to research will accelerate the discovery and advancement of technology and therapies.
The Coalition has been working with regulatory agencies in re-evaluating the approval process for determining the clinical and economic utility of new technology.
The Coalition’s members have demonstrated that they can:
- Lead the discussion on policies that impact coverage and payment
- Help facilitate the discussion of the cost of care in determination of care decisions
- Support the care decision process between the patient and the physician not dependent on coverage or reimbursement
- Shift emphasis to support inclusion of new therapies within the healthcare system and professional societies
- Emphasize the need for a clear and consistent coverage and reimbursement review and approval process
- lead the movement towards the use observational studies to provide evidence of clinical and economic utility through data registries developed in collaboration with CKC physicians and CMS of designed to expand available evidence that SRS can improve patient outcomes while lowing economic costs
- Be a strong voice on Capitol Hill and at the Federal level representing our cancer centers, physicians and patients
- Effectively change payment decisions at the MAC level
We are facing major health care reform at the same time we are realizing major advances in cancer medicine. Thousands of patients have already benefited from CyberKnife~ treatment yet patient access occurs mostly at urban centers prompted by well-informed patients and physicians. Much remains to be done to ensure that patients and their physicians are able to choose CyberKnife0 when they feel it is the right treatment.
Members of the CKC attend meetings, Days on the Hill with our Congressional and Senate
leadership and staff, network with the 155 centers across the United States, and contribute to a unique organization that is positioned to ensure that public policy, coverage, reimbursement and research are represented by the CyberKnife° Coalition’s membership. Members also learn about the latest coverage developments by CMS and commercial payers, hot issues, policy decisions and science and technology advances through webinars, meetings, and e-newsletter member updates.
CKC membership is open, but not limited to healthcare entities including universities, hospitals, cancer treatment centers, patient advocacy groups, healthcare or research entities interested in advancing the science or technology of stereotactic radiosurgery, and any patient who has been treated by CyberKnife® and is interested in being an advocate for advancing access to care.